02nd week of 2011 patent applcation highlights part 35 |
Patent application number | Title | Published |
20110008370 | NOVEL USE OF FLJ25416 GENE - Provided are a composition for diagnosing cancer or screening an anticancer drug comprising an FLJ25416 gene or an antibody directed to a protein expressed from the FLJ25416 gene, a composition for treating cancer comprising an inhibitor of the gene or an inhibitor of the protein expressed from the gene and a pharmaceutically acceptable carrier, and a kit for diagnosing cancer comprising at least one of the FLJ25416 gene and the protein expressed from the FLJ25416 gene. The FLJ25416 gene is expressed at high level in specific cancer cells, and induces an increase in proliferation rate of normal cells. The expression of the gene is suppressed, which results in an inhibitory effect on cancer cell growth. Thus, the FLJ25416 gene can be used as a target gene for diagnosis or treatment of cancer. | 2011-01-13 |
20110008371 | METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OX- O-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID FOR TREATMENT OF ANTECEDENT HEMATOLOGIC DISORDERS - Methods of treating, preventing or managing antecedent hematologic disorders, such as myelodysplastic syndrome, including chronic myelomonocytic leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cytarabine. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed. | 2011-01-13 |
20110008372 | ENHANCEMENT OF LIGHT ACTIVATED DRUG THERAPY THROUGH COMBINATION WITH OTHER THERAPEUTIC AGENTS - The efficacy of light activated therapy treatment is enhanced by use of additional therapeutic agents. Abnormal tissue is destroyed by light activated therapy, and the associated administration of one or more additional therapeutic agents can synergistically enhance the therapy. For example, the concepts disclosed herein encompass the use of the following agents in combination with light activated drug therapy: (1) agents that selectively inhibit heat shock protein 90 (Hsp90); (2) agents that inhibit the Hedgehog pathway (which is believed to play a central role in allowing the proliferation and survival of certain cancer-causing cells, and which is implicated in many of the most deadly cancers); and, (3) agents for reducing the anti-apoptotic effects of Bcl-2 or Bcl-xL. These agents can be used with light activated drug therapy individually, or in various combinations and permutations. | 2011-01-13 |
20110008373 | PRODRUGS OF CC-1065 ANALOGS - Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in which the prodrug also has a moiety, such as a disulfide, that can conjugate to a cell binding reagent such as an antibody. The therapeutic use of such prodrug conjugates is also described; such prodrugs of cytotoxic agents have therapeutic use because they can deliver cytotoxic prodrugs to a specific cell population for enzymatic conversion to cytoxic drugs in a targeted fashion. | 2011-01-13 |
20110008374 | Use of IL-1 Antagonists to Treat Gout - Methods of treating, inhibiting, or ameliorating gout, including chronic acute (refractory) gout, pseudogout, or drug-induced gout, in a human subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the incidence of a gout flare is reduced or inhibited. | 2011-01-13 |
20110008375 | Uses of Myostatin Antagonists - The present invention provides methods for treating disorders arising from hypogonadism, rheumatoid cachexia, cachexia due to burns, cachexia due to administration of chemical agents, cachexia due to diabetes, diabetic nephropathy, Prader Willi syndrome, excessive TNF-α, and other muscle-related, metabolic and inflammatory disorders by administering myostatin antagonists to subjects suffering from such disorders. | 2011-01-13 |
20110008376 | IMMUNOGENIC COMPOSITIONS CAPABLE OF ACTIVATING T-CELLS - The invention provides means and methods for producing and/or selecting immunogenic compositions capable of activating a T-cell and/or a T-cell response, comprising providing said composition with at least one crossbeta structure and testing at least one immunogenic property. | 2011-01-13 |
20110008377 | FELINE CD80, FELINE CD86, FELINE CD28, AND FELINE CTLA-4 NUCLEIC ACID AND POLYPEPTIDES - The present invention provides isolated and purified DNA encoding feline CD80 (B7-1) ligand, feline CD86 (B7-2) ligand, feline CD28 receptor, or feline CTLA-4 (CD152) receptor, as well as vectors comprising nucleic acid encoding feline CD80, feline CD86, feline CD28, or feline CTLA-4. The present invention provides a host cells transformed with CD80-encoding vectors, CD86-encoding vectors, CD28-encoding vectors, or CTLA-4-encoding vectors. The invention provides polypeptides encoded by the nucleic acid of feline CD80, feline CD86, feline CD28, or feline CTLA-4. The present invention provides a vaccine comprising an effective amount of polypeptides encoded by the nucleic acid of feline CD80, feline CD86, feline CD28, or feline CTLA-4. The present invention also provides vaccines which further comprise immunogens derived from pathogens. The invention provides for vaccines capable of enhancing an immune response. The invention also provides for vaccines capable of suppressing and immune response. | 2011-01-13 |
20110008378 | MODIFIED FLAGELLIN IMPROVED TOLL-LIKE RECEPTOR 5 STIMULATING ACTIVITY - Disclosed herein are flagellin mutants having an enhanced activity of stimulating the toll-like receptor-5 (hereinafter referred to as “TLR5”). More specifically, disclosed are flagellin mutants, prepared by point-mutating some of the amino acids of a TRL5 agonist flagellin so as to enhance the TRL-stimulating activity of the flagellin. | 2011-01-13 |
20110008379 | IMMUNOGENIC COMPOSITIONS CONTAINING ESCHERICHIA COLI H7 FLAGELLA AND METHODS OF USE THEREOF - Immunogenic compositions containing | 2011-01-13 |
20110008380 | Anaplasma Phagocytophilum (Aph) Antigens and Antibodies Specific for Anaplasma - The invention provides methods and compositions for the detection and treatment of | 2011-01-13 |
20110008381 | SUPPRESSION OF ALLERGIC INFLAMMATION BY ASCARIS HEME-BINDING PROTEIN (HBP) - This invention relates, e.g., to a method for suppressing inflammation (e.g. allergic inflammation, for example asthma caused by ragweed), a Th1-mediated condition and/or a Th2-mediated condition and/or a condition in which administration of an antioxidant would be beneficial, in a subject in need thereof, comprising administering to the subject an anitinflammatory-effective amount of | 2011-01-13 |
20110008382 | Compositions and methods using recombinant MHC molecules for the treatment of uveitis - Two-domain MHC polypeptides are useful for modulating activities of antigen-specific T-cells, including for modulating pathogenic potential and effects of antigen-specific T-cells. Exemplary MHC class II-based recombinant T-cell ligands (RTLs) of the invention include covalently linked β1 and α1 domains, and MHC class I-based molecules that comprise covalently linked α1 and α2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, to modulate T-cell activity, including by regulatory switching of T-cell cytokine and adhesion molecule expression, to treat conditions mediated by antigen-specific T-cells, for example autoimmune diseases or conditions such as acute and recurrent uveitis. | 2011-01-13 |
20110008383 | COMPOSITIONS OF TOLL-LIKE RECEPTOR AGONISTS AND MALARIA ANTIGENS AND METHODS OF USE - Compositions that include at least one fusion protein that includes at least a portion of at least one flagellin and at least a portion of at least one malaria antigen can be employed in methods that stimulate an immune response in a subject, in particular, sterile immunity and a protective immune response in a subject. | 2011-01-13 |
20110008384 | Antiviral activity from medicinal mushrooms - Compounds having unique antiviral properties are prepared from medicinal mushroom mycelium, extracts and derivatives. The compositions are derived from | 2011-01-13 |
20110008385 | Immunogenic composition - The present application relates to immunogenic compositions comprising staphylococcal PNAG and Type 5 and/or 8 capular polysaccharide or oligosaccharide from | 2011-01-13 |
20110008386 | USE OF MVA TO TREAT PROSTATE CANCER - The invention relates to compositions, kits, and methods for cancer prophylaxis and therapy using recombinant MVA viruses encoding tumor-associated antigens, such as PSA and PAP. The recombinant MVA viruses can induce B- and T-cell responses. The recombinant MVA viruses can be administered prior to, at the same time as, or after a taxane. | 2011-01-13 |
20110008387 | COMPOSITION CONTAINING HCMV PARTICLES - The present invention is related to a composition comprising an agent selected from the group comprising HCMV virions, HCMV dense bodies and HCMV NIEP, whereby the composition is capable of elucidating an immune response while the virions, the NIEP and/or the dense bodies being non-fusiogenic. | 2011-01-13 |
20110008388 | PIGLET FEED RATIONS HAVING LOW LEVELS OF FERMENTABLE CARBOHYDRATES - The present invention provides compositions comprising at least one acidifying agent, at least one immune stimulating agent, at least one antioxidant, and optionally, at least one tissue regeneration agent. The compositions comprise pre-mixes for inclusion in the diets of piglets, wherein the diets have low levels of fermentable carbohydrates. | 2011-01-13 |
20110008389 | RECOMBINANT ATTENUATED CLOSTRIDIUM ORGANISMS AND VACCINE - The present invention discloses attenuated | 2011-01-13 |
20110008390 | Production of a Viable, Storable Worm Egg Suspension - The present application describes a novel, advantageous purification method which guarantees the embryonation capability and the viability of a worm egg suspension. The | 2011-01-13 |
20110008391 | VACCINE COMPOSITION AND IMMUNIZATION METHOD - The present invention refers to the recombinant vaccine against canine visceral leishmaniasis containing the recombinant A2 protein and saponin, as an adjuvant, allowing the distinction between vaccinated and infected animals through conventional ELISA or immunofluorescence tests that employ antigens of promastigote forms of | 2011-01-13 |
20110008392 | VACCINE TARGETS AND DELIVERY SYSTEMS FOR CRYPTOSPORIDIUM - Compositions comprising the | 2011-01-13 |
20110008393 | NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 58P1D12 USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene 58P1D12 and its encoded protein, and variants thereof, are described wherein 58P1D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 58P1D12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 58P1D12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 58P1D12 can be used in active or passive immunization. | 2011-01-13 |
20110008394 | ACTIVE SUBSTANCES THAT INCREASE THE ACTIVATION THRESHOLD OF IMMUNE CELLS - The present invention relates to the use of active substances that increase the activation threshold of immune cell as an active principle for the preparation of a cosmetic or pharmaceutical composition, especially a dermatological composition. The invention also relates to a method for screening such active substances. | 2011-01-13 |
20110008395 | MIXED MICELLES INCLUDING AMPHIPATHIC CONJUGATES OF RNA AGENTS, AND USES THEREOF - Disclosed are improved pharmaceutical formulations for the delivery of RNA interference agents, such as antisense RNA, micro-RNA and siRNA. The formulations employ mixed micelles including amphipathic conjugates of the iRNA agents and amphipathic micelle-forming molecules with extended hydrophilic chains. Also disclosed are methods of using the pharmaceutical formulations to increase delivery of an iRNA agent to an intracellular target, and to decrease extracellular nuclease degradation of an iRNA agent in the formulations. | 2011-01-13 |
20110008396 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR CONDITIONS - The invention provides amphiphilic macromolecule encapsulates that are useful for treating cardiovascular diseases including conditions related to or emanating from atherosclerosis. | 2011-01-13 |
20110008397 | COMPARTMENTAL EXTRACT COMPOSITIONS FOR TISSUE ENGINEERING - The present invention concerns biologically-active cell-free scaffolds composed of extracts of cellular and/or extracellular compartments for use in tissue regeneration. The present invention also contemplates the novel concept of redesigning the biological scaffold by seeding cells thereon followed by cell elimination. Cells are seeded on the scaffold for a period of time during which a dynamic interaction occurs between the scaffold and the seeded cells, resulting in reshaping of the scaffold architecture and integration of newly synthesized matrix elements. Redesigning may improve the physical and biological characteristics of the scaffold, and also improve the matching of the scaffold to treat a specific target tissue or a specific patient, by seeding tissue-specific cells or by seeding cells which are autologous to a patient, respectively. | 2011-01-13 |
20110008398 | MEDICATED PATCH - Provided is a medicated patch containing a medicinal agent and an adhesive base material and having an acid value of no greater than 28, where the medicinal agent is varenicline or a pharmaceutically acceptable salt of varenicline. | 2011-01-13 |
20110008399 | USE OF ZERO-ORDER DIFFRACTIVE PIGMENTS - The present invention relates to compositions such as coatings, printing inks or cosmetics, which contain pigments comprising or consisting of a layer made of a material with an index of refraction that is higher than the index of refraction of the adjacent material by at least 0.25; whereas said layer has a zero-order diffractive micro-structure; whereas said layer acts as an optical waveguide and whereas said layer has a thickness between 50 nm and 500 nm; to processes for its manufacture and to its use. These pigments show a colour effect upon rotation and/or tilting, and it is believed that this colour effect is based on zero-order diffraction. | 2011-01-13 |
20110008400 | Digital Wipes And Method Of Handling - The present invention describes novel dental wipes and novel formulations for treating dental caries. The formulations may be used on the dental wipes or independently from the wipes. The wipe, when applied to the teeth, gums, tongue, and oral mucosa, helps treat dental caries and remove biofilm. | 2011-01-13 |
20110008401 | Cosmetic Compositions For Imparting Superhydrophobic Films - Compositions and methods are disclosed for imparting super-hydrophobic properties to cosmetics, in particular mascaras. The compositions comprise a hydrophobic film former in combination with hydrophobically-modified iron oxide pigments and/or carbon black. | 2011-01-13 |
20110008402 | SOULUBLE B-N-ACETYLGLUCOSEAMINIDASE BASED ANTIBIOFILM COMPOSITIONS AND USES THEREOF - The present invention provides compositions comprising an antibiofilm enzyme, a soluble β-N-acetylglucosaminidase similar to the dspB gene (DispersinB™), and an antimicrobial for preventing growth and proliferation of biofilm-embedded microorganisms in acute and chronic wounds, and methods of treatment. The invention further provides methods for preparing medical devices, and in particular, wound care devices using DispersinB™-based antimicrobial compositions. | 2011-01-13 |
20110008403 | MEDICAL ANTIMICROBIAL COMPOSITION AND MEDICAL DEVICE COMPRISING THE SAME - A medical antimicrobial composition includes a siloxanyl structure-containing polymer and an ammonium group-containing polymer, which is excellent in transparency, flexibility and mechanical properties, and also excellent in adhesion to a base resin with good mechanical properties, particularly to a silicone resin. The medical antimicrobial composition includes an ammonium group-containing polymer compound (A) dispersed in a siloxanyl structure-containing polymer (B) and a medical device comprising the medical antimicrobial composition. | 2011-01-13 |
20110008404 | Modification Of Biomaterials With Microgel Films - The various embodiments of the present disclosure relate generally to the modification of biomaterials with microgel films. More particularly, the various embodiments of the present invention are directed to the modification of biomaterials and medical devices with microgel thin films to alter a host's response to an implanted biomaterial or medical device. An embodiment of the present invention comprises a coated biomaterial comprising a non-fouling polymer film attached to at least a portion of a surface of the biomaterial, the non-fouling polymer film comprising a plurality of a cross-linked polymer microparticles, wherein at least a portion of the cross-linked polymer microparticles are covalently bonded to at least a portion of the surface of the biomaterial. | 2011-01-13 |
20110008405 | Hollow Tubular Drug Eluting Medical Devices - A method of a forming a hollow, drug-eluting medical device includes providing composite member having an outer member and a core member disposed within a lumen of the outer member. The composite member is shaped into a pattern. Openings are formed through the outer member of the composite member. The composite member is processed to remove the core member from the lumen of the outer member without harming the outer member, leaving a hollow tubular member already formed into the desired pattern. The lumen of the outer member is filled with a therapeutic substance. | 2011-01-13 |
20110008406 | Silk Fibroin Hydrogels and Uses Thereof - The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents, tissue space fillers, templates for tissue reconstruction or regeneration, cell culture scaffolds for tissue engineering and for disease models, surface coating to improve medical device function, or drug delivery devices. | 2011-01-13 |
20110008407 | COATING AND COATING METHOD - The present invention discloses a coating for a medical implant, wherein at least a part of said coating contains an osseointegration agent and the same and/or a different part of the coating contains an antimicrobial metal agent. | 2011-01-13 |
20110008408 | SOLID DOSAGE FORM FOR TREATING HEADACHES - A retrievable, sustained release, solid dosage form is provided for implanting into cranial bony canals and for prolonged release of an anesthetic, whereby treating neurovascular conditions, such as migraine. The dosage comprises an anesthetic contained in a polymeric carrier, and a retrieval member, the anesthetic being gradually released from the carrier. | 2011-01-13 |
20110008409 | PHARMACEUTICAL PREPARATION CONTAINING A GESTAGEN, AND KIT AND METHOD FOR TREATING ENDOMETRIOSIS USING THE PREPARATION - The pharmaceutical preparation for treating endometriosis contains at least 28, preferably 30, daily dose units, each of which contain dienogest, cyproterone acetate, or chlormadinone acetate at a daily dose that is at most twice that required to inhibit ovulation together with one or more pharmaceutical aids and/or carriers. The daily dose units are administered in a method of prophylaxis and/or therapy of endometriosis continuously during a time interval of at least 169 days or 25 weeks, preferably more than two years. The method effectively reduces endometriosis and associated pain, while undesirable side effects including bone density decrease are reduced or eliminated. | 2011-01-13 |
20110008410 | PHARMACEUTICAL COMPOSITION FOR TREATING MALARIA - The invention relates to a pharmaceutical composition in the form of rectal capsules, comprising a combination, effective against malaria parasites, of artemisinine or a derivative of artemisinine, particularly artesunate, with piperaquine or a pharmaceutically acceptable salt thereof, particularly piperaquine tetraphosphate, and having high activity against | 2011-01-13 |
20110008411 | METHOD OF TREATING PRURITIS - The present invention relates to a method of treating dermatologic pruritis. The skin involved with purities is covered with an organic cloth in order to make it more difficult to scratch. The contact of the organic cloth not only makes it difficult to scratch but adds a soothing feel thus lessening the tendency to need to scratch. | 2011-01-13 |
20110008412 | Oral Formulations for 5-HT-Receptor Agonists, Uses and Methods of Treatment Employing The Same - A pharmaceutically acceptable oral formulation comprising core material which comprises a therapeutically effective amount of a 5-HT-receptor agonist, or a pharmaceutically acceptable salt, solvate or derivative thereof, which core material is provided with a substantially water resistant coating comprising one or more substantially water resistant materials. | 2011-01-13 |
20110008413 | Compositions and Methods of Topical Drug Delivery for the Treatment of Carpal Tunnel Syndrome - The present invention generally relates to transdermal drug delivery systems. More particularly, the present invention provides compositions and transdermal drug delivery systems for the treatment and/or relief of symptoms associated with carpal tunnel syndrome or tendonitis. | 2011-01-13 |
20110008414 | METHOD FOR SYNTHESIZING CONFORMATIONALLY CONSTRAINED PEPTIDES, PEPTIDOMIMETICS AND THE USE THEREOF AS SYNTHETIC VACCINES - The present invention relates to methods for synthesizing conformationally constrained peptides and cyclic peptidomimetics obtainable by these methods which are conformationally constrained due an internal cross-link. This cross-link is formed between the side chain of an amino acid residue or analog and a (2S, 4S)4-functionalized proline residue. The invention further relates to the use of (2S, 4S)-4-functionalized proline residues as building units in the synthesis of such peptidomimetics and to the use thereof as antigens, alone or in combination with suitable immunopotentiating delivery systems, for example immunopotentiating reconstituted influenza virosomes to elicit an immune response in a mammal. Moreover, the invention also relates to pharmaceutical compositions containing the same. | 2011-01-13 |
20110008415 | NOVEL LIPOPHILIC COMPOSITIONS AND USES THEREOF - New co-lipids for use in combination with lipophilic compounds as nucleic acid vectors, for preparing a nucleic acid vector composition, and methods for introducing in vitro or in vivo a nucleic acid of interest into host cells, including a step of contacting host cells these nucleic acid vector compositions. The nucleic acid vector compositions have the combination (i) of a nucleic acid, cationic, lipophilic vector with (ii) a co-lipid. These nucleic acid vector compositions, in some embodiments, are present in the form of unilamellar or multilamellar vesicles. | 2011-01-13 |
20110008416 | ACOUSTICALLY SENSITIVE DRUG DELIVERY PARTICLES COMPRISING NON-LAMELLAR FORMING LIPIDS - Novel acoustically sensitive drug carrying particles comprising non-lamellar forming lipids are disclosed, as well as uses and methods thereof. The drug carrying particles accumulate in the diseased target tissue and efficiently release their payload upon exposure to acoustic energy. | 2011-01-13 |
20110008417 | IMMUNOMODULATING COMPOSITIONS AND USES THEREFOR - This invention discloses compositions that consist essentially of a Gag polypeptide or at least one portion thereof, and optionally antigen-presenting cells or their precursors, for treating or preventing lentiviral infections including the treatment or prevention of related acquired immunodeficiency diseases. In certain embodiments, the compositions consist essentially of a plurality of overlapping and/or non-overlapping peptides derived from a single Gag polypeptide or from different Gag polypeptides. | 2011-01-13 |
20110008418 | Compositions and Methods for the Treatment of Cancer - The present invention discloses anti-cancer compositions, and associated methods, including an anti-cancer composition comprising: a cellular energy inhibitor having the structure according to formula I | 2011-01-13 |
20110008419 | Vaccine Against Streptococcus Pneumoniae - The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to vaccines comprising a pneumococcal polysaccharide antigen, typically a pneumococcal polysaccharide conjugate antigen, formulated with a protein antigen from | 2011-01-13 |
20110008420 | SYNERGISTIC ANTIMICROBIAL PREPARATIONS CONTAINING CHLORITE AND HYDROGEN PEROXIDE - An anti-microbial preservative for use in ophthalmic and dermatologic products. The preservative includes from about 0.005 wt. % to about 0.20 wt. % chlorite compound and from about 0.005 wt. % to about 0.05 wt. % peroxy compound. Additionally, the preservative does not generate chlorine dioxide within the pH range of 5.0-8.8. Also included are an antimicrobial ophthalmic and dermatologic compositions for direct application onto an eye or skin of a living being including from about 0.005 wt. % to about 0.20 wt. % chlorite compound and from about 0.005 wt. % to about 0.05 wt. % peroxy compound. Also included are methods for treating dryness of the eyes and skin disorders (e.g., wounds, burns, infections, ulcerations, psoriasis, etc.) and for disinfecting and cleansing contact lenses while in place upon an eye by applying the composition to the eye or to the contact lens. | 2011-01-13 |
20110008421 | Liposome for delivery to posterior segment of eye and pharmaceutical composition for disease in posterior segment of eye - The invention provides a liposome for delivery to the posterior segment of the eye, comprising (A) a phospholipid, (B) a charged substance, and/or (C) a membrane-reinforcing substance; the liposome having a rigidity that provides the liposome with cell membrane permeability, and having a mean particle diameter of 1 μm or less; and a pharmaceutical composition for a disease in the posterior segment of an eye, comprising a drug encapsulated in the liposome. The liposome is delivered to the posterior segment of the eye by instillation, and is non-cytotoxic; and the pharmaceutical composition for a disease in the posterior segment of the eye comprises the liposome. | 2011-01-13 |
20110008422 | SYSTEM FOR DELIVERY OF PROTEIN IN INSOLUBLE FIBRILLAR OR AGGREGATE FORM - A pharmaceutical composition containing a therapeutic protein which is particularly amenable to oral administration by providing stability in the gastrointestinal tract. Insoluble fibrils or aggregates of the therapeutic protein in the pharmaceutical composition are encapsulated in a lipidated glycosaminoglycan particle, coated with a multi-layer of lipids and lipid-glycosaminoglycan conjugates, or present as unencapsulated and uncoated insoluble fibrils or aggregates. | 2011-01-13 |
20110008423 | PHARMACEUTICAL COMPOSITIONS COMPRISING GRANULES OF PURIFIED MICROBIAL LIPASE AND METHODS FOR PREVENTING OR TREATING DIGESTIVE DISORDERS - The present invention relates to pharmaceutical compositions comprising granules containing at least one recombinantly produced purified microbial lipase, the use of said pharmaceutical compositions for the manufacture of a medicament for the prevention or treatment of certain diseases or disorders like pancreatic endocrine insufficiency, and a process for the manufacture of said pharmaceutical compositions. | 2011-01-13 |
20110008424 | Sustained Release Solid Formulations and Methods of Manufacturing the Same - Disclosed are a sustained release solid formulation comprising a drug, for example, oxycodone or its pharmaceutically acceptable salt, in a water-insoluble matrix, which comprises a wax type excipient and copovidone, and thus, has increased compressibility and fluidity and reduced adhesiveness, and a method of preparing the same. | 2011-01-13 |
20110008425 | Treatment for Attention-Deficit Hyperactivity Disorder - A method for treating Attention Deficit/Hyperactivity Disorder (ADHD) in humans and the symptoms associated therewith, inattentiveness, and hyperactivity with impulsivity, using eltoprazine and related compounds is provided. | 2011-01-13 |
20110008426 | MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING MYCOPHENOLATE AND PROCESSES THEREOF - Modified release pharmaceutical compositions comprising mycophenolate as the active agent or its pharmaceutically acceptable salts, esters, polymorphs, isomers, prodrugs, solvates, hydrates, or derivatives thereof, wherein the said composition exhibits a biphasic release profile when subjected to in-vitro dissolution and/or upon administration in-vivo are provided. The composition provides a drug release in a manner such that the drug levels are maintained above the therapeutically effective concentration (EC) constantly for an extended duration of time. Further, the difference between the maximum plasma concentration of the drug (Cmax) and the minimum plasma concentration of the drug (Cmjn), and in turn the flux defined as ((Cmax−Cmjn)/Cavg) is minimal. The present invention also provides process of preparing such dosage form compositions and prophylactic and/or therapeutic methods of using such compositions. | 2011-01-13 |
20110008427 | Microcapsules and Methods - The present invention relates to microcapsules and methods for the production of microcapsules using sterically stabilized colloidal particles wherein the microcapsule comprises a core and a shell and wherein the shell comprises a layer of sterically stabilised colloidal particles and is characterized by the fact that the microcapsule has a mean size from 1 to 100 microns. | 2011-01-13 |
20110008428 | SOLID PHARMACEUTICAL COMPOSITION COMPRISING A NON-PEPTIDE ANGIOTENSIN II RECEPTOR ANTAGONIST AND A DIURETIC - The present invention relates to a solid pharmaceutical composition comprising at least two layers, wherein the first layer contains a non-peptide angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof in a dissolving matrix and the second layer contains a diuretic or a pharmaceutically acceptable salt thereof. The invention also provides methods for the production of said pharmaceutical compositions. | 2011-01-13 |
20110008429 | Anti-Retroviral Combination - A pharmaceutical composition comprising a solid unit dosage form comprising:
| 2011-01-13 |
20110008430 | Solid Pharmaceutical Dosage Form - A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10. | 2011-01-13 |
20110008431 | THERAPEUTIC TABLET FOR POSTHERPETIC NEURALGIA AND METHOD OF TREATING POSTHERPETIC NEURALGIA - The present invention provides a tablet for treating postherpetic neuralgia and a method of treating postherpetic neuralgia with the use of the tablet. The therapeutic tablet for postherpetic neuralgia according to the present invention is characterized in comprising buprenorphine hydrochloride, having a double layer structure consisting of a quick-release layer and a sustained-release layer, wherein the tablet is adhesive to the oral mucosa. | 2011-01-13 |
20110008432 | Method for Treating a Patient in Need of Aspirin Therapy - The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering to the patient in need thereof a pharmaceutical composition in unit dosage form comprising aspirin, or a pharmaceutically acceptable salt thereof, and an acid inhibitor to the at risk patient and thereby decreasing the patient's risk of developing an ulcer. | 2011-01-13 |
20110008433 | Herbal Composition for Osteoarthritis - A novel herbal composition comprising of | 2011-01-13 |
20110008434 | SALT OF 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]AMINO]-2-PYRIMIDINYL- ]AMINO]BENZONITRILE - The present invention relates to a pharmaceutical composition comprising as active ingredient the hydrochloric acid salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile and to processes for their preparation. | 2011-01-13 |
20110008435 | Nanoparticulate and Controlled Release Compositions Comprising Aryl-Heterocyclic Compounds - The present invention provides a composition comprising ziprasidone useful in the treatment and prevention of schizophrenia and similar psychiatric disorders. In one embodiment, the composition comprises nanoparticulate particles comprising ziprasidone and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In another embodiment, the composition comprises a modified release composition that, upon administration to a patient, delivers ziprasidone in a bimodal, multimodal or continuous manner. The invention also relates to dosage forms containing such compositions, and to methods for the treatment and prevention of schizophrenia and similar psychiatric disorders. | 2011-01-13 |
20110008436 | Silk Fibroin Hydrogels and Uses Thereof - The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents, tissue space fillers, templates for tissue reconstruction or regeneration, cell culture scaffolds for tissue engineering and for disease models, surface coating to improve medical device function, or drug delivery devices. | 2011-01-13 |
20110008437 | Silk Fibroin Hydrogels and Uses Thereof - The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents, tissue space fillers, templates for tissue reconstruction or regeneration, cell culture scaffolds for tissue engineering and for disease models, surface coating to improve medical device function, or drug delivery devices. | 2011-01-13 |
20110008438 | Bone Repair Composition and a Method of Making the Same - Bone repair composition and method of making the same, the bone repair composition being formed by firstly mixing a first aqueous calcium phosphate suspension with bone graft granules to form an intermediate mixture. The intermediate mixture is then mixed with a second aqueous calcium phosphate suspension, wherein the first aqueous calcium phosphate suspension contains a lower weight concentration of calcium phosphate than the second aqueous calcium phosphate suspension. | 2011-01-13 |
20110008439 | DULOXETIN COMPOSITION - The present invention relates to a stable pharmaceutical pellet composition comprising duloxetine or a pharmaceutically acceptable salt thereof and a method for making such composition. In particular, the composition comprises duloxetine hydrochloride and a separating layer comprising a water soluble inorganic salt. | 2011-01-13 |
20110008440 | NOVEL NANOCOMPOUND MATERIALS WITH INFRARED, ULTRAVIOLET AND VISIBLE ELECTROMAGNETIC RADIATION BLOCKING PROPERTIES AND METHOD FOR OBTAINING THEM - The present invention refers to novel nanocomposite materials with protection properties against infrared and ultraviolet-visible radiation, to the method for obtaining them, which comprises the stages of reducing the size of the laminar particles by mechanical action, filtering, removing organic matter, removing crystalline oxides and hard particles that are not subject to modification, obtaining laminar fines or laminar structure, pre-treating laminar structures by means of precursors, and adding the product resulting from the previous stages in liquid or dry state to a plastic matrix. The invention also refers to the use of said materials for different industry fields. | 2011-01-13 |
20110008441 | THERMORESPONSIVE ARGININE-BASED HYDROGELS AS BIOLOGIC CARRIERS - Cationic poly(ester amide) (PEA)-based hydrogels are provided. The hydrogels are fabricated from unsaturated L-arginine base poly(ester-amide) (UArg-PEA) precursors, pluronicDA precursors, or a combination of UArg-PEA and pluronicDA precursors at predetermined precursor composition ratios. PluronicDA/UArg-PEA hybrid hydrogels and pure pluronicDA based hydrogels are thermoresponsive and biodegradable, while pure UArg-PEA base hydrogels are biodegradable but not thermoresponsive. UArg-PEA based, pluronicDA based and hybrid hydrogels can be synthesized from unsaturated arginine-based PEA salts and/or unsaturated pluronic acid polymers. Unsaturated pluronic acid polymers can be synthesized by reacting pluronic acid with acryloylchloride to provided functional vinyl groups at the two chain ends of pluronic acid. The hydrogels can be used to carry and/or release molecules or compounds such as bioactive compounds, can function as biologic carriers for a variety of biomedical applications. | 2011-01-13 |
20110008442 | Dendritic Macroporous Hydrogels Prepared by Crystal Templating - The present invention includes a hydrogel and a method of making a porous hydrogel by preparing an aqueous mixture of an uncrosslinked polymer and a crystallizable molecule; casting the mixture into a vessel; allowing the cast mixture to dry to form an amorphous hydrogel film; seeding the cast mixture with a seed crystal of the crystallizable molecule; growing the crystallizable molecule into a crystal structure within the uncrosslinked polymer; crosslinking the polymer around the crystal structure under conditions in which the crystal structure within the crosslinked polymer is maintained; and dissolving the crystals within the crosslinked polymer to form the porous hydrogel. | 2011-01-13 |
20110008443 | PHOTOCROSSLINKED BIODEGRADABLE HYDROGEL - A photocrosslinked biodegradable hydrogel includes a plurality of natural polymer macromers cross-linked with a plurality of hydrolyzable acrylate cross-links. The hydrogel is cytocompatible and produces substantially non-toxic products upon degradation. | 2011-01-13 |
20110008444 | COMPOSITION FOR THE FORMATION OF GELS - A composition, which upon activation, spontaneously forms a cross-linked hydrogel in aqueous liquid, includes:
| 2011-01-13 |
20110008445 | SUSPENSION OF ASCORBIC ACID IN GLYCERIN AND PROCESS FOR PRODUCTION THEREOF - A suspension of ascorbic acid in glycerol or in glycerol comprising diglycerol, in which the content of ascorbic acid is 13% by mass or greater, and further in which 8 to 12% by mass of the ascorbic acid is dissolved in glycerol or in glycerol comprising diglycerol, and the rest of ascorbic acid is precipitated in the form of microcrystals having a particle diameter of 25 μm or smaller and is uniformly dispersed in the suspension. The suspension of ascorbic acid in glycerol is useful as a base material for cosmetics containing ascorbic acid which exhibits excellent feel in the use (spreadability and smooth feel on application to the skin). | 2011-01-13 |
20110008446 | Method of Drug Delivery - A drug delivery method for effective drug application is disclosed in this invention. In this method, a micro-carrier delivers an encapsulated, desired drug directly to targeted sites without significant interactions with other components in the biological system in the pathway. In one embodiment, a micro-carrier containing encapsulated drug is first delivered to the general area for treatment. It then scans the area and selectively attaches itself the cell site or organ location to be treated. Finally, the desired drug contained in the micro-carrier is released to the attached cell or organ. In another embodiment, a micro-device is first used to process the general area to be treated to enhance differentiation in properties (such as surface charge) between healthy cells and unhealthy cells (such as cancer cells). Drug encapsulated in the micro-carrier is next applied to preferentially attach onto the targeted sites (such as cancer cell sites) to be treated. Finally, drug is released from the micro-carrier onto the sites to be treated. Such micro-carrier preferably contains multiple functions comprised of at least two functions from the group of sensing, analyzing, logic processing, surface treatment, position detection, motion, injecting, delivering, cutting functions, removing functions, biodegradation and disintegration. | 2011-01-13 |
20110008447 | CARRIER COMPRISING NANODIAMOND - The present invention provides a carrier including a nanodiamond (ND) particle and a linker covalently bound to the ND particle, in which the linker is presented by the formula: —R | 2011-01-13 |
20110008448 | Diketopiperazine Salts for Drug Delivery and Related Methods - Drug delivery systems have been developed based on the formation of diketopiperazine carboxylate salts and microparticles containing the same. The systems may further comprise a bioactive agent. Related methods for making and using the biologically active agent delivery compositions are also provided. In certain embodiments, the pharmaceutically acceptable salts described can be formed by removal of solvent by methods including distillation, evaporation, spray drying or lyophilization. | 2011-01-13 |
20110008449 | Human Specific Escherichia Coli Strains - The present invention relates to human specific | 2011-01-13 |
20110008450 | Slow Release Compositions - The present invention relates to the provision of micron or sub-micron sized particles formed from one or more water-soluble crystals comprising a surface coating comprising one or more bioactive molecules wherein the particles are prepared such that in use the release of the bioactive molecule(s) is/are delayed and/or continually released over a period of time. Processes for the preparation of said particles, as well as the particles themselves are described, as well as uses of the particles. | 2011-01-13 |
20110008451 | COMPOSITIONS AND METHODS FOR CONTROLLED DELIVERY OF INHIBITORY RIBONUCLEIC ACIDS - Polymeric nanoparticles encapsulating inhibitory ribonucleic acids (RNAs) and methods of their manufacture and use are provided. Advantageous properties of the nanoparticles include: 1) high encapsulation efficiency of inhibitory RNAs into the nanoparticles, 2) small size of the nanoparticles that increases cell internalization, and 3) sustained release of encapsulated inhibitory RNAs by the nanoparticles that allows for administration of an effective amount of inhibitory RNAs to cells or tissues over extended periods of time. Encapsulation efficiency of inhibitory RNAs into the nanoparticles is greatly increased by complexing the inhibitory RNAs to polycations prior to encapsulation. Methods of using the polymeric nanoparticles for treating or inhibiting diseases or disorders are provided. | 2011-01-13 |
20110008452 | MEDICINAL AGENT FOR TREATING FATNESS, DIABETES, AND DISEASES ASSOCIATED WITH IMPAIRED GLUCOSE TOLERANCE - The inventive medicinal agent comprises antibodies against beta-subunit of insulin receptor in an activated form produced by means of repeated serial dilution and an external action performed according to homeopathic technology. The inventive method for producing a solid medicinal formulation for perorally treating fatness, diabetes, and other diseases associated with impaired glucose tolerance, consists in mixing the effective amount of carrier, which is showered in a fluidised layer by a water-alcohol dilution of antibodies in the form active against the beta-subunit of the insulin receptor produced by combining the repeated serial dilution, thereby reducing the concentration of antibodies, and an external action according to homeopathic technology, and is dried at a temperature equal to or less than 35° C., with pharmaceutically acceptable additives and in subsequently pelleting the mixture thus obtained by means of direct dry compression. | 2011-01-13 |
20110008453 | Stable Corticosteroid Nanoparticulate Formulations And Methods For The Making And Use Thereof - Disclosed are stable corticosteroid nanoparticulate formulations, methods of making and therapeutic uses thereof. | 2011-01-13 |
20110008454 | IMMEDIATE RELEASE PHARMACEUTICAL GRANULE COMPOSITIONS AND A CONTINUOUS PROCESS FOR MAKING THEM - A pharmaceutical or veterinary granule composition in the form of a mixture consisting essentially of: (i) at least one drug classifiable as Class II or Class IV of the Biopharmaceutical Classification System, wherein said drug (i) constitutes from 0.5% to 20% by weight of the composition, and excipients, said pharmaceutical or veterinary granule composition providing a drug release of at least 70% within 10 minutes in water, (ii) a first excipient being a maltodextrin representing from 40% by weight to 80% by weight of said composition, (iii) a wetting amount of a second excipient being a polyethylene glycol having a weight number molecular weight between 300 and 5,000, said second excipient comprising a solid fraction and a liquid fraction, and representing from 15% to 40% by weight of said composition, and optionally one or more pharmaceutically acceptable fillers selected from the group consisting of hydrocolloids, glidants, lubricants, surfactants and diluents, wherein the weight ratio of said first excipient (ii) to said second excipient (iii) is in a range from 1:1 to 5:1. | 2011-01-13 |
20110008455 | Crosslinked Protein Nanocrystals, Crosslinked Protein Nanoaggregates and Method of Preparation Thereof - This invention relates to crosslinked protein nanoparticles and a method for producing the same. The method comprises the preparation and nanonization (i.e., size reduction to the nanoscale) of protein nanoparticle precursor materials—i.e., crosslinked proteins of the micron or greater size—via mechanical or hydrodynamic shear, mechanical crushing, sonic cavitation and/or hydrodynamic cavitation. | 2011-01-13 |
20110008456 | Controlled Release Corticosteroid Compositions and Methods for the Treatment of Otic Disorders - Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s). | 2011-01-13 |
20110008457 | COMPOSITIONS AND METHODS FOR MODULATING LIPID COMPOSITION - The present subject matter relates to a novel herbal and oil composition and methods for modulating fatty acid composition and metabolism in an animal. In one aspect, the subject matter involves a composition comprising rosemary extract, oregano extract, and a polyunsaturated oil. In a particular embodiment, the polyunsaturated oil is fish oil or a derivative thereof. In some embodiments, the present subject matter relates to methods for modulating essential dietary fatty acid composition of lipoprotein particles or cell membranes, modulating essential fatty acid metabolism, regulating the activity of lipoxygenases and cyclooxygenases, improving cardiovascular health, and/or inhibiting cell proliferation diseases and disorders. | 2011-01-13 |
20110008458 | Process for removing growth factors from platelets - A sub-atmospheric, negative pressure is applied to a growth factor starting material, such as whole blood, to release growth factors and plasma in a non-destructive medium. The released growth factors having a weight of about 70-76 kDaltons are applied in either a filtered or unfiltered state to a wound to promote healing of the wound. The released growth factors are applied topically to the area of a surface wound to effect healing. The released growth factors are also injected into soft tissue, such as a torn tendon, to promote tissue growth and healing. The growth factors are released in one method from a patient's own blood. In another method the growth factors are released from a whole blood source and freeze dried by conventional lyophilization. Then at a later date, the freeze dried product is reconstituted by normal saline for treatment of a patient's wound or for use in a surgical procedure. | 2011-01-13 |
20110008459 | Universally applicable blood plasma - A universally applicable blood plasma obtainable by a process comprising the steps of mixing blood or blood plasma of blood groups A and B optionally blood or blood plasma of blood group AB without admixing substantial amounts of blood or blood plasma derived from blood group 0. | 2011-01-13 |
20110008460 | BIOMIMETIC HYDROXYAPATITE COMPOSITE MATERIALS AND METHODS FOR THE PREPARATION THEREOF - The present invention is related to methods for preparing composite materials, which include nanoscale hydroxyapatite, and the composite materials and articles prepared therewith. | 2011-01-13 |
20110008461 | INHIBITOR SCAFFOLD FOR THE INHIBITION OF THE ENZYME PHOSPHOENOLPYRUVATE CARBOXYKINASE - A PEPCK inhibitor can include identifying a molecule that has a size capable of fitting into and interacting with the PEPCK binding site and at least one of the following: (a) a first terminal substituent having co-planar atoms acting as metal ligands to the active site metal ion PEPCK; (b) at least one of an atom or substituent at positions 2 or 3 from the first terminal substituent includes a neutral carbon center or include an oxygen, sulfur, selenium, or other atom with similar physiochemical properties; (c) at least one of an atom or substituent at positions 2 or 3 from the first terminal substituent is devoid of an electropositive atom or substituents; or (d) a second terminal substituent opposite of the first terminal substituent, said second terminal substituent having an atom that is a hydrogen boding acceptor and/or is negatively charged. | 2011-01-13 |
20110008462 | SYSTEM AND METHOD FOR THERAPEUTIC APPLICATION OF DISSOLVED OXYGEN - A system and method for generating an oxygen enriched aqueous solution for therapeutic application includes a diffuser comprising a first diffusing member having a surface incorporating surface disturbances, and a second diffusing member positioned relative to the first diffusing member to form a channel through which an aqueous solution and oxygen gas may flow. A reservoir containing the aqueous solution is connected to a pump that draws the aqueous solution from the reservoir and inputs the aqueous solution into the diffuser. The aqueous solution is moved through the channel relative to the surface disturbances to create cavitation in the aqueous solution to diffuse the oxygen gas into the aqueous solution to produce an oxygen enriched aqueous solution. | 2011-01-13 |
20110008463 | COMBINATIONS OF HYDROXYPYRION COMPOUNDS AND SILVER COMPOUNDS - The present invention relates to combinations of hydroxypyrion compounds, and silver compound which provide an improved biocidal effect. More particularly, the present invention relates to compositions comprising a combination of a hydroxypyrion compound selected from 1-hydroxy-2-pyridinone, ciclopirox, ciclopirox olamine, piroctone, piroctone olamine, rilopirox, or a salt thereof, together with one or more silver salts selected from silver acetate, silver alginate, silver azide, silver citrate, silver lactate, silver nitrate, silver perchlorate, silver sulfate, silver chloride, silver thiocyanate, silver-sodium-hydrogen-zirconium phosphate, silver sulfadiazine, silver cyclohexanediacetic acid and disilver 2,5-dichloro-3,6-dihydroxy-2,5-cyclohexadiene-1,4-dione in respective proportions to provide a synergistic biocidal effect. Compositions comprising these combinations are useful for the protection of any living or non-living material, such as crops, plants, fruits, seeds, objects made of wood, thatch or the like, engineering material, biodegradable material and textiles against deterioration due to the action of microorganisms such as bacteria, fungi, yeasts, algae, virusses, and the like. | 2011-01-13 |
20110008464 | METHODS AND COMPOSITIONS FOR TREATING THYROID-RELATED MEDICAL CONDITIONS WITH REDUCED FOLATES - The present invention provides methods and compositions for treating thyroid-related medical conditions. Many thyroid-related medical conditions exist that go undiagnosed and untreated. These conditions may be prevented and treated with reduced folates and vitamin B12. Administration of reduced folates and vitamin B12 will prevent or treat cerebrospinal folate deficiency, which is linked to thyroid-related medical conditions. Administration of reduced folates and vitamin B12 will also prevent or treat conditions associated with masked megaloblastic anemia and hypothyroidism, and other conditions brought upon through improper thyroid function. Additionally, it is commonplace to treat many thyroid conditions with anti-thyroid drugs or thyroid stimulating drugs. This practice alone is also responsible for causing, or not beneficially addressing, adverse conditions that can be prevented or treated through the methods and compositions discussed herein. | 2011-01-13 |
20110008465 | SESQUITERPENE FORMULATIONS, KITS AND METHODS OF USE THEREOF - A pharmaceutical composition comprising a water insoluble sesquiterpene, one or more antioxidants and one or more solubilizers selected from the group consisting of an oil, PEG400, a derivative of castor oil and ethylene oxide, and polysorbate 80, and methods of use thereof. | 2011-01-13 |
20110008466 | METHODS AND COMPOSITIONS FOR ALTERING CELL FUNCTION - The present invention relates to compositions and methods for altering cell function. In particular, the present invention provides compositions comprising selenium (e.g., SEL-PLEX) and methods of using the same (e.g., as a therapeutic and/or prophylactic treatment). Additionally, the present invention demonstrates that specific forms of selenium (e.g., SEL-PLEX), when administered to a subject, possess the ability to alter (e.g., reduce) gene expression in various tissues (e.g., compared to expression in subjects not administered selenium). | 2011-01-13 |
20110008467 | SODIUM THIOSULFATE-CONTAINING PHARMACEUTICAL COMPOSITIONS - Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate. | 2011-01-13 |
20110008468 | Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders - Aspects of this invention are related, at least in part, to the use of chemical compounds able to inhibit GSK-3 and/or to stabilize β-catenin and formulations thereof. Some aspects of this invention relate to compositions comprising such compounds. Some aspects of the invention provide methods of using such compounds and/or compositions in the treatment of subjects having a neurological disease and/or psychiatric disorder. Some aspects of this invention provide methods of using ruboxistaurin, enzastaurin, sunitinib, midostaurin, lestaurtinib, 7-hydroxystaurosporine, and/or Chir99021 in the treatment of subjects having a neurological disease and/or psychiatric disorder. In some embodiments, compounds are administered in combination with Lithium. | 2011-01-13 |
20110008469 | ANTIMICROBIAL COMPOSITION AND METHODS AND APPARATUS FOR USE THEREOF - There is presented an alkaline disinfectant in the form of a multi-component composition, with each component being relatively benign until mixed with the other components in a ready-to-use solution. The invention further relates to the use of the composition in a variety of applications and apparatus for mixing and dispensing thereof. Furthermore, the invention relates to the use of components that synergistically provide effective biocidal activity in a broad spectrum of organisms, including germs, molds, viruses, bacteria, bacteria spores, or other microbes or pathogens. The composition provides a chemical system that kills all known plants, animals and microbes by raising pH and rapidly, but indirectly, transporting hydroxide into cells by use of ammonia compounds and/or amine compounds as neutral transporters. The composition components synergistically operate together to provide a disinfecting/cleaning composition useful for many different applications. | 2011-01-13 |